Depression is a known risk factor for CVD [
31‐
33]. The COMT Val
158Met genetic variation influencing COMT enzyme activity has previously been associated with risk for depression [
12], and risk for CVD [
8,
13,
14]. The identity of the at risk allele has varied between studies, although a meta-analysis demonstrated high activity
COMT Val allele as risk allele for depression. An influence of gender as well as childhood adversity on the Val
158Met association with depression has previously been reported [
15], although a recent meta-analysis found no Val
158Met association to depression in any gender [
16]. Using a large population-based Swedish cohort of adults we here show for the first time that the COMT Val
158Met genotype, corresponding to high COMT enzymatic activity, implies an increased risk of CVD especially for those who had depression up to 14 years earlier. Thus, both an additive and a multiplicative interaction between depression and COMT Val
158Met for risk of CVD were detected. Additionally, this risk of CVD by high COMT activity genotype and depression was more pronounced in women compared to men. Both mild and severe depression were considered, scored at two time points for each participant, and the original cohort was randomly selected among Swedish nationals in the Stockholm County.
There are previous reports demonstrating a relationship between COMT Val
158Met and acute coronary events, ischemic stroke and CVD risk factors like hypertension and lipid abnormalities [
13,
14,
34]. The results from these studies are however not fully consistent with regard to which allele implies a disease risk and the influence of depression on the relationship was not previously assessed. Hagen and coworkers reported that high COMT activity (Val/Val genotype) is overrepresented in male and female Norwegians with systolic hypertension (≥140 mmHg) (
n = 2591) [
34]. This finding was confirmed in a Chinese population (
n = 3079) showing that high activity COMT (Val/Val) was associated with cardio -metabolic risk factors including hypertension and high triglyceride levels [
35]. Accordingly, Eriksson et al. reported a protective effect of low activity COMT (Met/Met or Val/Met) against myocardial infarction in Swedish and Finnish hypertensive men (
n = 522) [
8]. Contrary to this, low activity COMT (Met/Met or Val/Met) was associated with acute coronary events in Finnish men (
n = 792) [
13], and with high systolic and diastolic blood pressure and abdominal obesity in Swedish men (
n = 1302) [
14]. The reason for the discrepancy in risk allele identity between the aforementioned studies is unclear but could in part be related to different ranges of estrogen levels, and thereby different gender and age distributions. Accordingly, we found that high activity
COMT (Val/Val)*depression was associated with increased CVD risk in women, but not in men. This sex-based difference might partially be explained by the difference in estrogen activity between men and women. Estrogen plays an important role in the cardiovascular system and COMT is key in the degradation of estrogens. Thus, the association between COMT Val/Val and CVD in females might reflect altered levels of estrogen and its metabolites [
8,
36]. Moreover, estrogen signaling influences
COMT transcription through estrogen response elements in the
COMT promoter [
37,
38]. The COMT enzyme metabolizes also dopamine and catecholamines which regulate both mood and cardiovascular functions through wide-spread expression of their receptors. Therefore, our Val/Val-CVD association finding may partly be due to effects of COMT enzyme activity variation on the metabolism of these transmitters. The influence of depression on the Val/Val-CVD association may in part be through increased inflammation and oxidative stress often seen in the depressed state, [
39] which could potentiate a high COMT enzyme activity effect on cardiovascular function. Of the individuals in PART 11% had a non-Swedish origin, among those the vast majority had a Nordic origin. The Swedish population at time of sampling had no strong internal genetic borders [
40] and especially the southern/middle parts of Sweden (from where the participants of this study are derived) were more genetically homogeneous [
41].
Limitations
Firstly, due to the self-administered sampling at home, the depression cases that participated did likely not represent those most severely depressed. Secondly, only 42% provided DNA samples. Factors associated with public refusal to consent to DNA biobanking in the PART have been reported and reveal that, a lack of personal relevance of DNA contribution and feelings of discomfort related to the DNA being used for purposes other than the respective study were the reasons for low participation [
42] The association between depression and risk of later CVD is unlikely influenced by refusal to consent to DNA biobanking. Another limitation of the study is that we did not have individual data on psychotropic drugs medication. Antipsychotic drugs are known to increase risk for CVD [
43]. Also, we did not include data from the cause of death register and the outpatient register, hence we might have missed those who died or visited outpatient department due to IHD or stroke without prior hospitalizations.